Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: "CORRECTION, 5:22 p.m., Oct. 15, 2014: This story has been amended to remove the incorrect original declaration that the $250,000 donation was given before the suits were filed. According to copies of the filings provided by Zac Petkanas, a spokesman for Davis, one of several suits singled out by Davis as the basis of her ad was filed in January 2014, before the donation the next month. This change led us to change our rating of the statement from Half True. (See the original fact check here.) In a TV ad, Wendy Davis said Greg Abbott took a hefty campaign donation before siding with a hospital against patients injured and killed by a drug-taking surgeon. Davis, the Fort Worth state senator and Democratic gubernatorial nominee, consistently depicts Abbott, the state attorney general and Republican choice for governor, as an unethical insider beholden to powerful interests. The narrator of the ad, titled ""Operation,"" says: ""He was a Texas surgeon, performing operations while reportedly using cocaine. Two people died, others were paralyzed. Doctors spoke out,"" the narrator says, ""but the hospital did nothing to stop him. Families and victims sued the hospital. ""Then, weeks after accepting a quarter-million-dollar campaign contribution from the hospital's chairman, Greg Abbott got involved, using his office to go to court -- against the victims."" Abbott solicited and accepted the donation, we confirmed, and the state intervened in lawsuits pitting patients against the hospital, though he got involved to defend a state law. Senator’s backup By email, Davis spokesman Zac Petkanas said Davis based her claim in part on a July 30, 2014, news story in the Dallas Morning News stating that not long after the chairman of the board of the Baylor Health Care System, which owns the Baylor Regional Medical Center at Plano, donated $250,000 to Abbott’s campaign, Abbott weighed in on federal lawsuits against the hospital where a neurosurgeon allegedly had done damage to patients. News report and interview of donor We confirmed from Abbott’s campaign finance filings with the state and an interview with the board chairman and donor, Temple businessman Drayton McLane, that McLane donated $250,000 to Abbott’s campaign in January 2014. That donation, the News story said, came after McLane gave the campaign $100,000 in 2013. Before the six-figure contributions, the story said, McLane’s biggest donation to Abbott had been $25,000. Abbott’s campaign recorded the $250,000 donation as arriving Jan. 23, 2014 -- the very date one of the relevant federal lawsuits were filed against the hospital. Then again, we realized with a nudge from Petkanas after this article initially appeared, one of the several lawsuits was filed Dec. 27, 2013, weeks prior to McLane's contribution. His $250,000 check, a photo of which McLane’s office emailed to us, was dated Jan. 21, 2014. The News story said Abbott and McLane had each told the paper the two had not discussed the lawsuits. McLane also said he didn’t know about the case before contributing the $250,000, the paper said, and he stressed he had no personal financial interest in the nonprofit hospital system; the chairman’s post is unpaid. By phone, McLane told us he’s known Abbott since before Abbott, originally a Houston lawyer, won election as a Harris County state district judge in 1992 and gave the $250,000 after Abbott asked him for a large contribution. McLane said he hadn’t spoken with the Republican nominee since. Asked what he expected for the eye-catching contribution, McLane said: ""I’m not expecting to get anything back. I believe in strong good government. Unfortunately, on both sides, there are heavy contributions."" On top of not knowing about the lawsuits described by Davis before making his donation, McLane said, he hadn’t long been chairman of Baylor Scott & White Health, which owns the Plano facility, having become chairman when healthcare systems merged in October 2013; McLane previously chaired Scott & White Healthcare. Abbott in court As noted in the News, the federal suits against the Baylor system and Plano hospital challenge the constitutionality of a state law requiring the plaintiffs to prove Baylor acted with actual intent to harm patients -- which the suing plaintiffs/families call an impossibly stiff burden. Petkanas of Davis’ campaign provided copies of several lawsuits filed on behalf of patients and families, each one alleging a neurosurgeon, Christopher Duntsch, was permitted by the Plano hospital to perform surgeries under the influence of illegal drugs and alcohol, causing harm. Those suits also challenge action by state lawmakers in 2003, while overhauling laws regulating lawsuits seeking damages,  to delete a definition of ""malice"" in the law, hence ""eliminating a common-law right arbitrarily in light of the purposes of the statute leaving only an impossible condition before liability will attach,"" the lawsuits say. A spokeswoman for the attorney general’s office, Lauren Bean, emailed us the state’s nearly identical March 24, 2014, filings in three plaintiff challenges to the law. In the filings, the state said it has a statutory right to intervene in a case when the constitutionality of a state law is at issue. On March 31, 2014, a week after the state filed its request, U.S. District Judge Jorge A. Solis granted the request to intervene ""for the purpose of defending the constitutionality of Texas law,"" Solis wrote. His order said no parties to the litigation objected. It’s undisputed an attorney general may seek to get involved in a federal suit to defend a state law, but some lawyers told us it’s up to the official to do so -- or not. Attorney Kay Van Wey, who represents some plaintiffs in the suits against the hospital, said by email Abbott’s move was unusual and unreasonable, though she didn’t object, she said, because there is no legal way to do so; we didn’t divine what she meant by that. Van Wey further said Abbott ""is defending a law that essentially gives immunity to hospitals for credentialing dangerous physicians. The law, as it now stands, denies access to the courts for good, taxpaying Texas citizens, who through no fault of their own, were butchered by a highly dangerous surgeon. ""Even if we prove the hospitals were grossly negligent in hiring and retaining a dangerous surgeon,"" Van Wey said, ""...it isn't enough under the current state of the law. In Texas, we have to prove ‘malice,’ meaning we have to prove the hospital had a subjective intent to harm the patient. That is considered to be an impossible standard. It is clearly an erroneous and completely unfair law. He didn't have to intervene in our lawsuits. He chose to."" The News story quoted Bean saying McLane’s contributions played no role in his decision to intervene in the suits. Besides, Bean said, the ""state is not defending the hospital or the doctor in this case — or their alleged conduct. If the hospital or doctor have violated the law, then they will be held accountable, and nothing in the state’s court filings opposes the plaintiffs,"" patients and families, ""on that front,"" she said. Bean gave us the agency’s full response sent to the News. In it, Bean said the state ""will not be putting on any defense of any action by the hospital or any doctor. The state will not put on any evidence or make any argument whether the hospital’s actions or the doctor’s actions violate the law. The state does not condone, support or defend the actions of the hospital or doctor. The only thing the state will argue is that the law is not unconstitutional."" Outside lawyers An Austin lawyer who helped write the 2003 change told us he believes the attorney general was bound to defend the revised law as Abbott is doing. Michael Hull emailed: ""The AG intervention is consistent with federal and state law. The AG is defending the constitutionality of a statute. His office has not taken a position on the facts alleged in the petition nor has the AG chosen to defend the hospital or the doctor."" Hull later said such constitutional challenges are rare, ""but when challenges do occur, it is common for the AG to defend the constitutionality of the statute."" Hull and Michael Guajardo, the Dallas president of the Texas Trial Lawyers Association, each pointed out any litigant is required to notify the state of a federal challenge to a state law’s constitutionality We asked if that formal notice touched off Abbott’s intervention. Not so, Bean said, adding the attorney general’s office has no record of receiving the notice, which court filings say was sent by certified mail. Instead, Bean said, Jonathan Mitchell, the state solicitor general, learned of the suits from a March 10, 2014, news story in the Texas Lawyer magazine. Petkanas, told we hadn’t uncovered proof the McLane donation prompted Abbott to enter the lawsuits, said by email the ad didn’t assert a cause and effect -- only that McLane gave his campaign donation before Abbott intervened. Our ruling Davis said that weeks ""after accepting a quarter-million-dollar campaign contribution"" from a hospital board chairman, Greg Abbott went to court against victims of a drug-taking neurosurgeon. Davis’ statement needs clarification – that Abbott’s intervention was limited to defending the constitutionality of Texas’ tort-reform laws. That makes this statement . – The statement is accurate but needs clarification or additional information."

Output: "Weeks after accepting a quarter-million-dollar campaign contribution"" from a hospital board chairman, Greg Abbott went to court against victims of a drug-taking neurosurgeon."


Input: Consider Input: There’s no discussion of cost, even to mention that statins are relatively inexpensive these days and are mostly generically available. To its credit, the article does mention the cost of a calcium scan. We learn that “anywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years.” That’s helpful information. It also notes that the observed benefit is less for older patients. The story could have added that even those numbers might disputed by some experts who perceive no meaningful benefit. For example, one review found being on a statin does not help people with low risk for heart disease live longer. The story does a service by highlighting the harms of statins. It explains: “The most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines. People taking statins are also at a higher risk of developing diabetes, which is harder to reverse.” It also mentions the potential for overtreatment with the use of coronary calcium scans. However, we wish it had included absolute numbers. The story says harms are “uncommon,” but provides no data to back that up. Rates of adverse effects with statins have been measured at 1 to 10%, which makes them “common” in the definition of the European Medicines Agency. Also noteworthy is that some contend that adverse effects of statins have not been reliably reported. The story doesn’t explain the quality of the study, or of studies on which current guidelines are based. We don’t explicitly learn that this is a modelling study. In other words, this study consisted mostly of reinterpretations of math, not re-evaluations of real-life patients. The researchers said they were unable to obtain enough data on all possible harms and age-specific data on some harm outcomes, “so the risk thresholds we determined may still be too low.” There is no disease-mongering here. This story includes sources that weren’t involved in the study. The study’s authors reported no conflicts of interest. The story could have acknowledged the influence of pharmaceutical companies in creating guidelines for statin use. The alternative of not taking a statin was the key message here, and that’s laudable. However, we have a couple of concerns. First, we learn that “some statins were more effective than others, with atorvastatin (the generic name for Lipitor) being the best of the bunch.”  However, the story doesn’t explain on what basis some statins are “more effective.” In fact, some statins may be more effective at lower cholesterol, but the study found that no statin rises above others when it comes to the outcomes that counts most to patients — reducing cardiovascular deaths. Also, the story doesn’t mention lifestyle interventions — diet and exercise. The story makes it clear that statins are widely prescribed. The story states this an attempt to better weigh the benefits and harms of statin use. There was a good range of interviewees with no reliance on a news release

Output: Before Starting A Statin, Talk It Over With Your Doctor


Input: Consider Input: Irish-born William Campbell and Japan’s Satoshi Omura won half of the prize for discovering avermectin, a derivative of which has been used to treat hundreds of millions of people with river blindness and lymphatic filariasis, or elephantiasis. China’s Tu Youyou was awarded the other half of the prize for discovering artemisinin, a drug that has slashed malaria deaths and has become the mainstay of fighting the mosquito-borne disease. She is China’s first Nobel laureate in medicine. Some 3.4 billion people, most of them living in poor countries, are at risk of contracting the three parasitic diseases. “These two discoveries have provided humankind with powerful new means to combat these debilitating diseases that affect hundreds of millions of people annually,” the Nobel Assembly at Sweden’s Karolinska Institute said. “The consequences in terms of improved human health and reduced suffering are immeasurable.”  Today, the medicine ivermectin, a derivative of avermectin made by Merck & Co, is used worldwide to fight roundworm parasites, while artemisinin-based drugs from firms including Novartis and Sanofi are the main weapons against malaria. Omura and Campbell made their breakthrough in fighting parasitic worms, or helminths, after studying compounds from soil bacteria. That led to the discovery of avermectin, which was then further modified into ivermectin. The treatment is so successful that river blindness and lymphatic filariasis are now on the verge of being eradicated. Omura, 80, said the real credit for the achievement should go to the ingenuity of the Streptomyces bacteria, whose naturally occurring chemicals were so effective at killing off parasites. “I really wonder if I deserve this,” he said after learning he had won the prize. “I have done all my work depending on microbes and learning from them, so I think the microbes might almost deserve it more than I do.”  Omura is professor emeritus at Kitasato University in Japan, while Campbell is research fellow emeritus at Drew University in Madison, New Jersey. “This was the work of a team of researchers so it is by no means my work, it’s our work,” said Campbell, 85, who learned of his prize in a pre-dawn phone call from Reuters that woke him at his home in North Andover, Massachusetts. “In the first decade, there were 70 authors that I co-authored papers with. That gives you some idea of the number of people involved,” he said. Tu, meanwhile, turned to a traditional Chinese herbal medicine in her hunt for a better malaria treatment, following the declining success of the older drugs chloroquine and quinine. She found that an extract from the plant Artemisia annua was sometimes effective but the results were inconsistent, so she went back to ancient literature, including a recipe from AD 350, in the search for clues. This eventually led to the isolation of artemisinin, a new class of anti-malaria drug, which was available in China before it reached the West. Tu, 84, has worked at the China Academy of Traditional Chinese Medicine since 1965. World Health Organization spokesman Gregory Hartl said the award of a Nobel prize for the discovery was a great tribute to the contribution of Chinese science in fighting malaria. “We now have drugs that kill these parasites very early in their life-cycle,” said Juleen Zierath, chair of the Nobel Committee. “They not only kill these parasites but they stop these infections from spreading.”     Death rates from malaria have plunged 60 percent in the past 15 years, although the disease still kills around half a million people a year, the vast majority of them babies and young children in the poorest parts of Africa. The 8 million Swedish crowns ($960,000) medicine prize is the first of the Nobel prizes awarded each year. Prizes for achievements in science, literature and peace were first awarded in 1901 in accordance with the will of dynamite inventor and businessman Alfred Nobel. Last year, the medicine prize went to three scientists who discovered the brain’s inner navigation system.


Output: Beating parasites wins three scientists Nobel prize for medicine.